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Abstract 
Background: In an attempt to increase the therapeutic potential for myocardial regeneration, there is a quest for 
new cell sources and types for cell therapy protocols. The pathophysiology of heart diseases may affect cellular char-
acteristics and therapeutic results.
Methods: To study the proliferative and differentiation potential of mesenchymal stem cells (MSC), isolated from 
bone marrow (BM) of sternum, we made a comparative analysis between samples of patients with ischemic (IHD) or 
non-ischemic valvular (VHD) heart diseases. We included patients with IHD (n = 42) or VHD (n = 20), with average age 
of 60 years and no differences in cardiovascular risk factors. BM samples were collected (16.4 ± 6 mL) and submitted 
to centrifugation with Ficoll-Paque, yielding 4.5 ± 1.5 × 107 cells/mL.
Results: Morphology, immunophenotype and differentiation ability had proven that the cultivated sternal BM cells 
had MSC features. The colony forming unit-fibroblast (CFU-F) frequency was similar between groups (p = 0.510), but 
VHD samples showed positive correlation to plated cells vs. CFU-F number (r = 0.499, p = 0.049). The MSC culture 
was established in 29% of collected samples, achieved passage 9, without significant difference in expansion kinet-
ics between groups (p > 0.05). Dyslipidemia and the use of statins was associated with culture establishment for IHD 
patients (p = 0.049 and p = 0.006, respectively).
Conclusions: Together, these results show that the sternum bone can be used as a source for MSC isolation, and that 
ischemic or valvular diseases do not influence the cellular yield, culture establishment or in vitro growth kinetics.
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Background
In recent years, great attention has been given to the 
use of cell-based therapy in cardiology, with a num-
ber of clinical trials [1–3] that have been subjected to 
systematic reviews and meta-analyses [4–6]. Most of 
these studies have used bone marrow mononuclear cells 
(BMMC) obtained by iliac crest bone marrow (BM) aspi-
ration [5]. The BM contains two types of adult stem cells: 
the hematopoietic stem cells give rise to blood cells [7], 
and the non-hematopoietic stem cells, or mesenchy-
mal stem cells (MSC), contribute to the regeneration of 
mesenchymal tissues such as bone, cartilage and muscle 
[8]. In addition to their ability to differentiate into cel-
lular components of the heart, such as endothelial cells 
and cardiomyocytes [9, 10], MSC are also able to release 
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a great number of cytokines and chemokines, which can 
mediate the processes of tissue regeneration [8, 11]. For 
all these reasons, MSC have attracted increasing atten-
tion as a source of cells for cardiac regenerative therapy.
Since MSC are present in a low frequency in the 
BM (0.001–0.01%) [12], their use in clinical protocols 
requires ex  vivo expansion and maintenance for 4–5 
[13] or 6–8  weeks [14], depending on the pathology, so 
that a sufficient number of cells can be produced [15]. 
It is known that in aged individuals MSC have reduced 
frequency, capacity of expansion in culture [16, 17] and 
cellular fitness [18], factors that compromise the expan-
sion of these cells in culture. Another problem relates to 
the limited capacity of expansion of BM cells after isola-
tion and injection in patients who had had a myocardial 
infarction with consequent cardiomyocyte loss [19].
Considering that different heart diseases have different 
pathophysiological mechanisms, it is expected that cellu-
lar therapy for each of these diseases would have different 
results. This is the case of using cell therapy for heart fail-
ure determined by myocardial ischemia or by valve dis-
eases, with BMMC or MSC [15, 20, 21]. The assessment 
of the ex  vivo behavior of MSC isolated from elderly 
heart diseases patients with similar risk factors may pro-
vide valuable information for the choice of cell sources. 
The characterization of bone marrow-derived MSC is 
extremely important, since these patients represent of 
the main groups of interest for cell therapy and any loss 
in number or in cellular functionality can generate pro-
found consequences for tissue regeneration processes.
The present study aims to quantify and analyze MSC 
isolated from sternal BM of patients with ischemic or 
non-ischemic valvular heart disease, evaluating the fre-
quency of colony forming unit-fibroblast (CFU-F), the 
potential of establishing in vitro cultures and the kinetics 
of cultures until reaching senescence, as well as the dif-
ferentiation potential. Clinical characteristics of patients, 
as well as the pharmacology in using, were also analyzed 
and correlated to the ability of establishment of cell 
cultures.
Methods
Patients
Patients with ischemic heart disease (IHD) or non-ischemic 
valvular heart diseases (VHD), between 50 and 75 years old, 
and referred for coronary artery bypass grafting or valve 
replacement surgery respectively, were included. Exclu-
sion criteria were presence of hematologic diseases, previ-
ous heart complications and cancer diagnosis. The study 
was approved by the Research Ethics Committee of Insti-
tuto de Cardiologia (Process Number 4397/09), and was 
conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all patients.
Evaluation of clinical parameters
The clinical data were obtained from medical records, 
where we evaluated the age, the gender, the presence of 
systemic arterial hypertension (defined by blood pressure 
greater than 140/90 mmHg and by the use of antihyper-
tensive medication), dyslipidemia (total cholesterol lev-
els greater than 200 mg/dL, triglycerides grater than 150 
and HDL-cholesterol grater than 40 for men and 50 for 
women, in addition to the use of lipid-lowering medica-
tion), diabetes mellitus (defined by glycemia exceeding 
180 mg/dL and the use of oral hypoglycaemic or insulin), 
smoking (patients were considered smokers as declared 
smoking at the time of entering the study or who declared 
having stopped smoking until 10  years before entering 
the study). It was also considered the use of medications 
such as angiotensin-converting enzyme inhibitor, statins, 
antiplatelet drugs, diuretics, beta blockers and insulin.
Isolation and cultivation of sternum MSC
The sternal BM was aspirated using a 10  mL syringe 
and 1.20 × 40 mm needles, with 1.5 mg EDTA/mL BM. 
BMMC were isolated by centrifugation over Ficoll-Paque 
Plus (GE Heathcare Life Sciences, Uppsala, Sweden). 
Cells from the mononuclear layer were washed, counted 
with trypan blue and resuspended in complete culture 
medium, composed of low-glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco-Carlsbad, SP, Brazil) 
with 15% fetal bovine serum (Cultilab, SP, Brazil), 100 U/
mL penicillin and 100  mg/mL streptomycin (Cultilab). 
Cells were plated in duplicate samples in 12-well culture 
plates, at 2.8 × 106 BMMC/cm2 and incubated at 37  °C 
in a humidified, 5%  CO2 incubator for 72 h, when non-
adherent cells were removed by changing the medium. 
The medium was changed twice weekly. For expansion 
of cultures the cells were passaged (split) when they 
reached 80–85% of area confluence. For this, the medium 
was removed and adherent cells were washed twice with 
phosphate-buffered saline (PBS, pH 7.4) and incubated 
with 0.05% Trypsin–EDTA (Gibco) for about 5  min at 
37  °C. Cultures were considered successful when reach-
ing the passage 3 (P3). Plastic ware was from Becton–
Dickinson (BD Biosciences, San Jose, CA, USA).
Proliferation kinetics
MSC were analyzed for proliferation capacity in two 
stages. In the first one, BMMC were initially plated in 
duplicate samples in 12-well culture plates, at 2.8 × 106 
cells/cm2 and passaged at 80–85% confluence. From 
P1–P3, cells were plated at different densities (10, 18 
and 75  ×  103 cells/cm2, respectively). From passage 4 
on, a protocol adapted from Stolzing et al. [18] was used. 
Briefly, MSC were plated in triplicate samples in 6-well 
culture plates at  104  cells/cm2 and passaged at 80–85% 
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confluence at the same density. Cells were maintained in 
culture and counted at every passage, until proliferation 
stopped.
The population doubling (PD), cumulative population 
doubling (CPD) and cumulative days were determined as 
previously described [22]. The population doubling time 
(PDT) was calculated at P3 and P9 as t/n, where t is the 
duration of culture in days and n is the number of PD.
Immunophenotyping
Cells were used in P3, centrifuged, and incubated for 
30 min at room temperature in the dark with PE-conju-
gated (anti-CD49e, CD166, CD14, CD146, HLA-ABC, 
CD105 and CD73), FITC-conjugated (anti-CD31, CD45, 
CD51/CD61, CD44, CD29, HLA-DR, CD90 and CD106), 
PerCP-conjugated anti-CD34, APC-conjugated anti-
CD13 antibodies and respective isotype controls (BD 
Biosciences). The cells were analyzed using a FACS Cali-
bur cytometer (Becton–Dickinson, San Diego, CA, USA) 
with the CellQuest Pro software. At least 10,000 events 
were collected. Forward scatter (FSC) and side scatter 
(SSC) were used for gating on staining cells and exclud-
ing cell debris.
MSC differentiation
MSC cultures (P3) at 80% confluence were kept for 
21 days in osteogenic- or adipogenic-inducing media [23, 
24]. Controls were maintained in standard medium for 
the same period. Experiments were performed in trip-
licates. Differentiation was analyzed with Alizarin Red 
S or Oil Red O (Sigma-Aldrich, St Louis, MO), respec-
tively, according to Kretlow et al. [24]. In each well, five 
randomly selected fields were photographed with an 
AxioCam camera (Carl Zeiss, Hallbergmoos, Germany). 
Stained areas were quantified using the Image-Pro Plus 
software and expressed as percentage of the total ana-
lyzed area.
Colony forming unit‑fibroblast assay
The CFU-F assay was performed as previously described 
[18, 25]. BMMC were resuspended in complete culture 
medium and plated in duplicate samples in 6-well culture 
plates, at 5 × 105,  106 and  107 BMMC/well. Medium was 
changed on days 3 and 8 of culture. On day 14th, cul-
tures were fixed and stained with May-Grünwald-Giemsa 
and colonies (groups of  >30 fibroblastoid cells) were 
counted. The CFU-F frequency was calculated based on 
the respective input cell number as CFU-F per 1 ×  106 
BMMC.
Statistical analyses
The data were tested for normality using a Kol-
mogorov–Smirnov test. The results are expressed as 
mean  ±  standard deviation (SD) or median and inter-
quartile intervals. Groups were compared using paramet-
ric tests (Student’s t test) for CPD, cumulative days, and 
CFU-F or non-parametric tests (Mann–Whitney test) 
for analysis of PDT and MSC differentiation. The Chi 
square test was used to compare the rate of success in 
establishing MSC cultures, and the Fisher’s exact test for 
comparing characteristics between groups. The level of 
significance was set at 5% for all tests. Statistical analyses 
were performed with the SPSS software package, version 
19.0, and Graphpad Prism 5.
Results
Characterization of the sample
A total of 62 patients were included in the study (IHD, 
n  =  42; VHD, n  =  20). As presented in Table  1, most 
characteristics were similar between groups. The use of 
diuretics was higher in the VHD group, male sex fre-
quency, statins use, use of antiplatelets and beta-blockers 
was higher in IHD patients, as expected.
MSC from sternum of IDH and VHD patients can be 
established and cultivated in vitro
The mean volume of sternal BM collected was 16.4 ± 6 mL, 
which yielded in average 4.5 ± 1.5 × 107 cells/mL of tissue. 
We considered a successful establishment when cultures 
reached the P3. However, between the 42 IHD samples, 
6 reached only P1 and other 3 samples stop proliferation 
before P2; and, in 20 isolated samples of VHD patients, 2 
stopped proliferation before P2, being in culture for up to 
40 days. Thus, of the 62 samples analyzed, the successful 
Table 1 Clinical characteristics of  patients with  ischemic 
(IHD) or non-ischemic valvular heart disease (VHD)
Age described as mean ± standard deviation; other variables as n and 
percentage (%)
IHD ischemic heart disease, VHD non-ischemic valvular heart disease
Statistical analysis by Fisher’s exact test (α = 5%)
Variables IHD (n = 42) VHD (n = 20) p
Age (years) 59.30 ± 6.61 62.35 ± 8.82 0.135
Male 37 (88.1) 13 (65.0) 0.043
Hypertension 34 (81.0) 14 (70.0) 0.349
Diabetes mellitus 13 (31.0) 3 (15.0) 0.226
Smoking 30 (71.4) 10 (50.0) 0.155
Dyslipidemia 6 (14.3) 3 (15.0) 1.000
Medications in use
 Angiotensin-converting enzyme 
inhibitor
26 (61.9) 13 (65.0) 1.000
 Statins 28 (66.7) 7 (36.8) 0.049
 Antiplatelet drugs 30 (71.4) 7 (35.0) 0.012
 Diuretics 6 (14.3) 12 (60.0) 0.001
 Insulin 1 (2.4) 1 (5.0) 0.545
 Beta-blockers 30 (71.4) 6 (30.0) 0.002
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establishment of cultures characterized as MSC was 29% 
(n = 18). The percentage of MSC established cultures did 
not differ (p = 0.189) between the groups IHD and VHD 
(23.8%, n  =  10, and 40%, n  =  8, respectively) (Fig.  1a). 
Considering the influence of the clinical parameters in the 
MSC establishment, we found that the presence of dys-
lipidemia, as well as patients who used statins, both in the 
IHD group, were features that were significantly associated 
with the presence of in vitro cell cultivation (p = 0.049 and 
p  =  0.006, respectively). No other parameter (reported 
in Table  1) showed association with the presence or the 
absence of culture establishment of MSC. The same was 
observed when patients of IHD and VHD groups were 
considered separately or grouped (p  >  0.05). Young cul-
tures (P1 to P3) showed a fibroblast-like morphology, with 
a well-delimited nucleus and with regular borders (Fig. 1b). 
In older cultures (≥P3), the fibroblastic morphology was 
modified, and larger cytoplasms and irregular borders as 
well as intracellular debris were observed (Fig. 1c).
Cultured cells from sternum of IHD and VHD patients 
have characteristic MSC immunophenotype and ability 
to in vitro differentiation
MSC cultures isolated from IHD and VHD patients 
showed a characteristic surface profile, with low or no 
expression (<2% of events) of hematopoietic (CD34, 
CD14, CD45) and endothelial (CD51/61, CD31, CD146) 
markers and HLA-ABC, as well as of HLA-DR and 
CD106, and presence of CD73, CD105, CD166, CD90, 
CD13, CD29, CD49e, CD44 (Fig.  2). The analysis of 
cell size and granularity (FSC and SSC, respectively) 
and counts for antibody-isotype controls may be seen 
in the Additional file  1. Further, in samples from both 
groups, the osteogenic and adipogenic differentiations 
were observed in 60 and 75%, respectively, of MSC cul-
tures treated with inducing media comparing to controls 
(Fig. 3). Besides, there was no difference between the adi-
pogenic (p =  0.461) or osteogenic (p =  0.635) differen-
tiation rates for samples isolated from patients with IHD 
and VHD.
The type of heart disease does not affect proliferative 
capacity of MSC isolated from sternum
Quantification of CFU‑F frequency
Figure 4 shows the average CFU-F count obtained from 
BMMC samples isolated from sternum of patients with 
IHD or VHD. The CFU-F frequencies were similar to 
both cardiopathies, being 1/1.1  ×  106 and 1/1.2  ×  106, 
respectively (p = 0.510). There was a positive correlation 
(r = 0.499; p = 0.049) between the number of plated cells 
and the number of CFU-F in the VHD group, however, 
the same did not occur for the IHD group (r  =  0.188; 
p = 0.302).
Proliferation and expansion kinetics
From P1 to P3, the expansion rates of individual MSC 
cultures derived from IHD and VHD samples showed a 
large variation, with eightfold duplication of the initial 
population in some of the cultures and only one in others 
(Fig. 5a–c). From passage 4 on, however, cultures showed 
Fig. 1 Quantification analysis of sternum MSC establishment and cell morphology. a Percentages of samples with or without establishment of cell 
cultures (overcoming P3) for ischemic (IHD) and non-ischemic valvular heart disease (VHD) (p = 0.189). b Young (P1) and c older (P9) cultures, under 
phase contrast microscopy (left) and stained with May-Grünwald-Giemsa (right). Original magnifications ×100
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a low proliferation capacity or stopped proliferation 
(Fig. 5b–d). Four of the 10 established cultures from IHD 
samples, were maintained after P4, and only three were 
maintained after P7 (Fig. 5a, b). Six of the 8 MSC cultures 
established from VHD samples were maintained after 
P4 and only two after P6 (Fig. 5c, d). No differences were 
observed between the two groups of cultures regarding 
the expansion rate (CPD, Fig. 6a–c) in each passage (P1, 
p = 0.905; P2, p = 0.447; P3, p = 0.827; P4, p = 0.839; P5, 
p =  0.221; P6, p =  0.514; P7, p =  0.703; P8, p =  0.740; 
Fig. 2 Representative immunophenotype profile of MSC cultures isolated from sternum of ischemic (IHD) and non-ischemic valvular heart dis-
ease (VHD). Positive (right) and negative (left) staining for MSC, hematopoietic and endothelial cell populations analyzed by flow cytometry
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Fig. 3 Differentiation ability of MSC cultures from sternum of ischemic (IHD) and non-ischemic valvular heart disease (VHD) patients. Representa-
tive micrography of positive (induced, right) and negative (control, left) staining for a Alizarin Red S (osteogenic marker) and for b Oil Red O (adipo-
genic marker). Original magnifications ×100
Fig. 4 CFU-F counts from sternal BM of ischemic (IHD) and non-ischemic valvular heart disease (VHD) patients. The BMMC separated from sternal 
BM were seeded in values varying between 5 × 105 and 1 × 107 cells. a Bars show the average number of colony forming unit-fibroblast (CFU-F) 
counted after 14 days and related to 1 × 106 BMMC seeded for each disease. b Representative image of CFU-F from IHD (upper wells) and VHD (bot-
tom wells) samples in different concentrations of seeding
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P9, p = 1.00). No differences were observed between the 
two groups in the number of days to reach 80–85% con-
fluence (cumulative days, Fig. 6b–d) in each passage (P1, 
p = 0.351; P2, p = 0.439; P3, p = 0.283; P4, p = 0.789; P5, 
p = 0.757; P6, p = 0.771; P7, p = 0.881; P8, p = 0.583; P9, 
p = 0.484), or in the PDT measured at P3 (IHD, 7.7 days 
to 5.5–8.5  days—vs. VHD, 6.5  days to 4.5–8.8  days; 
p =  0.696) or P9 (IHD, 11.1  days to 5.2–15.8  days—vs. 
VHD, 7.4 days to 3.7–16.5 days; p = 0.730).
Discussion
The present study described for the first time the fre-
quency and the functionality of MSC isolated from the 
sternal bone marrow of two groups of patients with dis-
tinct heart diseases. We showed that cultures showed 
characteristics compatible to those established by the 
International Society for Cellular Therapy, including 
proliferation as plastic-adherent cells, immunopheno-
type (expression of CD105, CD73 and CD90 and low or 
no expression of CD45, CD14, CD34 and HLA-DR) and 
the capacity differentiation into mesodermal cell lineages 
[26]. These results show that the sternum of patients with 
IHD or VHD can be a source for collecting both BMMC 
and MSC, and that the type of heart disease does not 
influence the establishment of cultures. Since it is easier 
to collect sternal than femoral bone marrow in patients 
undergoing median sternotomy, this alternative source 
can be considered in cases of autologous cell therapy.
The proliferative capacity of MSC used in our study 
was confirmed in the first weeks and was maintained 
throughout the period of cultivation. Cultures were 
established from 30% of the samples, which could be 
explained by the fact that these are elderly patients, with 
lower bioavailability of red bone marrow and augmented 
cellular aging, which causes DNA damage, apoptosis and 
a reduction of the pool of undifferentiated cells and, con-
sequently, proliferative potential [27, 28]. However, no 
association was observed between age and establishment 
of culture (p = 0.465). On the other hand, the establish-
ment of MSC cultures was positively associated with 
presence of dyslipidemia in IHD patients and the use 
of statins. It is known that statins are able to modulate 
endothelial progenitor cells, another example of adult 
stem cell, increasing their in  vitro proliferative capacity 
[29]. In contrast, the presence of other factors inherent to 
heart diseases does not seem to affect the ability of estab-
lishment of MSC cultures.
The low frequency of CFU-F (1/1 × 106 MSC/BMMC) 
observed in the present study can also be related to low 
proliferative potential of cells isolated from the sternal 
compartment. The initial expansion of cultures is a result 
of CFU-F present in the sample (single cells that con-
tinue to divide to form colonies of cloned cells) [7], so 
Fig. 5 Proliferation kinetics of MSC isolated from sternum of ischemic (IHD) and non-ischemic valvular heart disease (VHD) patients. Cumulative 
population doubling (CPD) of individual MSC cultures derived from IHD (a, b) or VHD (c, d) samples. a, c From P1 to P3. b, d From P4
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that a lower number of colonies suggests a lower success 
in the establishment of cultures, besides changes in the 
functional capacity of MSC [18]. Age has been already 
shown to be closely related to the number of CFU-F, as 
reported by several studies [16, 18, 30, 31]. Baxter et al. 
[30], for example, reported a great difference in the num-
ber of CFU-F in BM samples from healthy donors of 
old age (59–75 years) and pediatric donors (0–18 years) 
(3.2  ±  1.7/106 vs. 29.0  ±  4.7/106 BMMC, respectively). 
Our study showed that the frequency of CFU-F obtained 
from the sternal BM of heart disease patients was 
approximately two times smaller. These results suggest 
that not only increasing age, but also the presence of spe-
cific factors associated with cardiovascular disease—such 
as molecules and drugs used that may affect common 
pathways to the proliferation and homing process—could 
decrease the regenerative capacity of endogenous BM 
stem cells [27]. Ito and Suda [32] suggested that meta-
bolic requirements of the BM, which direct adult stem 
cells to anaerobic glycolysis (keeping the cells undiffer-
entiated) or oxidative metabolism (which activates dif-
ferentiation), can control the process of exhaustion of the 
stem cell compartment. Thus, the stem cell compartment 
is directly affected by to the life history of the cardiac 
patient, related to maintenance of inflammatory states 
that disrupt homeostasis and accelerates regenerative 
processes.
Cultures established from sternal BM of the patients 
were also analyzed for morphology. During the initial 
period (P0–P3), the cells presented a fibroblastoid mor-
phology, but in later passages, modifications suggestive 
of senescence were observed. These changes included 
loss of fibroblastoid aspect, presence of irregular bor-
ders, wide cytoplasm and presence of intracellular debris. 
These differences were also reported for human MSC 
cultures isolated from the BM of healthy individuals 
[31] and for cultures of trabecular osteoblasts [33], sug-
gesting that they are imposed by the two-dimensional 
in vitro cultivation condition. Cultures older than P3–P4 
were more difficult to expand and/or lost the ability to 
proliferate, which is important since, even aiming at the 
use of MSC (which are considered the adult stem cells 
with greater therapeutic potential), clinical protocols for 
cardiovascular diseases require large cell numbers [34]. 
This decrease in proliferative potential of MSC was also 
reported by Choumerianou et al. [31], who observed that 
MSC isolated from children (4 ± 1 years old) were more 
easily expanded until, at least, P6 than cells from healthy 
Fig. 6 In vitro expansion kinetics of MSC isolated from sternum of ischemic (IHD) and non-ischemic valvular heart disease (VHD). a, c Average 
cumulative population doubling (CPD) and cumulative days in each passage of IHD and VHD samples. a, b From P1 to P3. c, d From P4. Sample size 
(n) is shown in Fig. 5
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adults (54  ±  5  years old), which were more difficult to 
expand after P4. The authors have also observed a rela-
tionship of these findings with shortening of telomeres 
presented by MSC from adults. Telomeres are known to 
play an important role in the molecular aging process of 
cells [35].
Few studies have compared cells isolated from dif-
ferent sites such as sternal and iliac crest. Adams et  al. 
[36] showed that MSCs isolated from equine sternum 
and ilium had similar characteristics, without difference 
between growth rates. In sheep, the sternum was consid-
ered a good source of bone marrow MSC, with cell divi-
sion cycle and proliferative potential similar to the cells 
from iliac bones, showing that a sample from one site is 
representative of the whole [37]. Human stromal stem 
cell populations reside in different tissues and the human 
MSC isolated from iliac crest, sternum and vertebrae 
bone marrow have also shown similar immunophenotype 
but different growth and differentiation abilities, suggest-
ing that they may not represent equivalent cell sources 
for therapeutic applications [38].
The limitations of our study are consistent to those 
involving collections of biological samples from patients 
(different sample collectors, different locations of the 
sternum for bone marrow aspiration, different volumes 
collected, etc.). Later, the influence of the pathophysi-
ological condition of the patient (presence of disease 
and associated factors) lead to low proliferative capacity 
of isolated cells, mainly in a two-dimensional system for 
in vitro growth, which in our case, represented approxi-
mately 30% of success in establishment. Anyway, in order 
to assist the medical conduct intending to use protocols 
based on isolated cells of the bone marrow, our group 
is also investigating the mechanisms involved with the 
homing of stem cells, mainly focused on the modulation 
of the chemokine stromal-derived factor-1 (SDF-1) and 
its receptor, CXCR4, beyond the inflammatory profile of 
patients. This data may identify if the cells are capable of 
being stimulated to cell migration and settlement in car-
diac tissue differentially in ischemic and valvular cardi-
opathies through the expression of these molecules.
Conclusions
We showed that it is possible to isolate and cultivate 
MSC from small volumes of sternal bone marrow of car-
diac patients. Valvular and ischemic heart diseases, even 
with variable pathological and physiological aspects, do 
not have different influences on the proliferative capacity 
or differentiation potential of the isolated MSC, so that 
the autologous cell therapy protocols with these cells can 
be designed for both diseases. However, the processes of 
expansion and exhaustion of the BM stem cell population 
are probably influenced/modulated by risk factors such 
as diabetes, hypertension, smoking, obesity and dyslipi-
demia, in addition to pharmacological therapy. These fac-
tors must be considered, as they may contribute to the 
failure of the proliferation of MSC cultures, necessary for 
autologous cell therapy. However, these cells can be safely 
isolated, and used in in vitro experiments, such as tests 
for drugs, besides transcriptome and proteome analy-
ses according to the different stages of the disease and 
patient condition. Additionally, MSC are known for their 
high potential for regeneration and secretion of parac-
rine factors [39]. In this context, the discovery of mecha-
nisms that can modulate and increase the therapeutic 
capacity of the MSC is a constant objective in this area of 
research, which aims at better therapeutic strategies for 
the therapy of cardiovascular diseases.
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